Predictive biomarkers of overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/− bevacizumab: Results from CALGB 90206 (Alliance)
- Citation:
- Clin Cancer Res vol 28 (13) 2771-2778
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 11
- Parents:
- 968
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233253
- Corr. Author:
- Authors:
- Andrew B. Nixon Susan Halabi Yingmiao Liu Mark D. Starr John C. Brady Ivo Shterev Bin Luo Herbert I. Hurwitz Phillip G. Febbo Brian I. Rini Himisha Beltran Eric J. Small Michael J. Morris Daniel J. George
- Networks:
- CA824, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-TN008
- Study
- CALGB-90206
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- bevacizumab, biomarker, IL-6, plasma, multiplex ELISA, renal cancer